STTR Phase I: Novel Molecularly Targeted Tracer for Specific and Sensitive Imaging of Cancer

STTR 第一阶段：用于癌症特异性和灵敏成像的新型分子靶向示踪剂

• 批准号: 1321424
• 负责人: Anka Veleva
• 金额: $ 22.5万
• 依托单位: Clave Biodesign, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1321424&HistoricalAwards=false
• 关键词: STTR; Phase; Novel; Molecularly; Targeted

This Small Business Technology Transfer Phase I project takes an innovative approach at tumor targeting by investigating an entirely novel tumor targeting platform that utilizes bone marrow derived, circulating tumor homing cells as natural vectors. Through screening of phage display peptide libraries we have identified high affinity peptide ligands that bind these cells with high specificity. These high affinity, high specificity peptide ligands and their applications for molecular imaging of tumor?s blood supply represent the innovation in this Phase I project. Radiolabeled peptide directed compounds will be synthersized and their potential to deliver molecular ?payloads? specifically to malignant vasculature in a mouse model of cancer will be characterized. The results from this development effort will provide proof-of-principle validation for a new targeting paradigm in which circulating tumor localizing cell populations can be exploited for highly transformative and innovative technology development for the benefit of cancer patients.The broader impact of this project and the commercialization of the molecular diagnostic tracer developed here will have important implications for furthering oncology care through personalized approaches: First, specific and sensitive imaging based on monitoring of homing of circulating cells to tumor tissue will be beneficial for tumor staging and re-staging. Second, in addition the outcomes of this development effort would provide more predictable information relevant to treatment that has been lacking so far. Close assessment of patient?s response to treatment by monitoring the presence or absence of circulating tumor homing cells would improve treatment outcomes and guide the development of personalized therapies. Third, especially promising clinical direction is to selectively deliver anti-angiogenic, and therapeutic compounds as anticancer strategies. Because endogenous cells are utilized as natural biologic vectors, the barriers to commercialization and clinical implementation of our innovative diagnostic tracer are much lower than for other emerging technologies.

这个小企业技术转让I期项目通过研究一种全新的肿瘤靶向平台，采用了一种创新的肿瘤靶向方法，该平台利用骨髓来源的循环肿瘤归巢细胞作为天然载体。通过噬菌体展示肽库的筛选，我们已经鉴定了以高特异性结合这些细胞的高亲和力肽配体。这些高亲和力、高特异性的多肽配体及其在肿瘤分子显像中的应用？的血液供应代表了这个第一阶段项目的创新。放射性标记的肽定向化合物将合成和它们的潜力，提供分子？有效载荷？特别是小鼠癌症模型中恶性脉管系统的特征。这项开发工作的结果将提供证据-该项目的广泛影响以及在此开发的分子诊断示踪剂的商业化将对通过个性化治疗促进肿瘤治疗产生重要影响。方法：首先，基于监测循环细胞归巢到肿瘤组织的特异性和灵敏性成像将有利于肿瘤分期和再分期。 第二，此外，这一发展努力的成果将提供迄今为止缺乏的与治疗有关的更可预测的信息。对患者进行密切评估？通过监测循环肿瘤归巢细胞的存在或不存在来监测患者对治疗的反应，将改善治疗结果，并指导个性化治疗的发展。第三，特别有前途的临床方向是选择性地递送抗血管生成和治疗性化合物作为抗癌策略。由于内源性细胞被用作天然生物载体，因此我们的创新诊断示踪剂的商业化和临床实施的障碍比其他新兴技术低得多。